Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
Public ClinicalTrials.gov record NCT04326036. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection
Study identification
- NCT ID
- NCT04326036
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- Black Tie Medical, Inc.
- Industry
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Interventions
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Procedure
- Centricyte 1000 Device
- IV Deployment Of cSVF In Sterile Normal Saline IV Solution Procedure
- Liberase Enzyme (Roche) Drug
- Sterile Normal Saline for Intravenous Use Drug
Procedure · Device · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2020
- Primary completion
- Jul 31, 2023
- Completion
- Jan 30, 2024
- Last update posted
- Feb 21, 2023
2020 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Robert W. Alexander, MD, FICS, LLC | Stevensville | Montana | 59870 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04326036, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 21, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04326036 live on ClinicalTrials.gov.